Gene expression of the Interleukin 6 signal transducer, IL6ST (gp130) associates with survival outcomes in breast cancer.

Shahan Mamoor

DOI: https://doi.org/10.31219/osf.io/6auzr

2020-03-19

Abstract:Breast cancer is a leading cause of death for women in the United States (1). The central reason women die from breast cancer is metastasis, or spread of cancer from the breast to foreign sites such as the bones, liver, brain and lungs (2). We integrated independent microarray datasets, one containing transcriptome data from primary tumors of the breast (3), and the other containing transcriptome data from metastases from women with breast cancer (4), each of which possess survival data associated with the patient from which each tumor or metastasis sample was obtained. By comparing tumor transcriptome data based on survival outcomes, we found that gene encoding the Interleukin 6 signal transducer, IL6ST, gp130 (5), was among the genes whose expression was most different between patients who survived greater or less than 18 months. In both primary tumors of the breast and in metastases, IL6ST was expressed at significantly higher levels in women who survived greater than 18 months. These data are consistent with a role for IL6ST as a biomarker, or prognostic indicator (6-8) to help predict which women can benefit from more or less intensive treatment regimens based on prediction of metastasis; moreover, IL6ST may be fundamentally linked with tumor progression and tumor aggressiveness highlighting potential for IL6ST as a therapeutic target in breast cancer.